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Conjunctival intraepithelial neoplasia (CIN), 
charac terised by dysplasia involving a partial to full 
thickness of the epithelium, and invasive squamous 
cell carcinoma (SCC) of the conjunctiva belong to 
a single disease spectrum termed ocular surface 
squamous neoplasia (OSSN).[1] In Western countries, OSSN was 
long regar ded as a relatively rare, slow-growing tumour primarily 
affecting elderly men,[2,3] but recent evidence suggests a 12-fold 
increased risk among patients with advanced HIV disease in the 
USA.[4,5] In sub-Saharan Africa (SSA), the incidence of OSSN has 
increased exponentially in recent years, and it is now the most common 
malignancy of the ocular surface in this region.[6] Moreover, relative 
to OSSN in Western countries, OSSN in SSA is more aggressive and 
affects younger individuals, who are typically females in the 3rd 
and 4th decades of life.[7-9] The rising incidence has been attributed 
to the HIV epidemic, as the majority of African individuals 
affected are HIV-infected.[5,10,11] Ultraviolet B radiation[12,13] and 
human papillomavirus (HPV)[14,15] have also been implicated in 
the pathogenesis of OSSN in this region. Surgical excision is 
the mainstay of treatment for OSSN,[16] but recurrence rates 
following excision remain unacceptably high, ranging from 15% 
to 52%.[1] In an effort to reduce recurrence rates, primary excision 
has been combined with various adjunctive therapies, including 
cryotherapy, chemotherapy and radiotherapy.[17] The present study 
describes the clinical characteristics, treatment modalities and 
preliminary outcomes among OSSN patients at a tertiary referral 
hospital in Gaborone, Botswana, a country with a population HIV 
seroprevalence of 17.1%.[18]
Methods
This retrospective cohort study included consecutive patients with 
OSSN presenting to Princess Marina Hospital (PMH), a tertiary 
hospital in Gaborone, Botswana, between 1 February 1998 and 
31 March 2008. PMH is the ophthalmology referral centre for the 
southern half of Botswana, treating almost 50% of all surgical ocular 
conditions in the country, including OSSN. The standard of care at 
PMH during the study period was as follows. Patients with a clinical 
diagnosis of OSSN determined by an ophthalmologist in the eye clinic 
were scheduled for surgical excision. Surgical excision specimens were 
sent to the pathology division of the National Health Laboratory of 
Botswana for diagnosis by a clinical pathologist. All OSSN patients 
treated during the study period received surgical excision. Adjunctive 
beta radiation applied during and following surgery was introduced, 
and became standard of care, in 2002. The source for beta radiation 
was strontium 90. Beta radiation at a dose of 6 000 centigray (cGy) 
was applied with an oval disc applicator to the base and margins of the 
excision site at the time of surgery, and was then given weekly at the 
same dose for 6 weeks. Patients were treated free of charge.
For the present study, patients with a diagnosis of OSSN were 
identified from existing surgical records as well as from pathology 
laboratory records. Patient characteristics and surgery-related data 
were collected, including age, sex, affected eye, date of surgical excision, 
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clinical diagnosis and histological diagnosis. 
Primary treatment modality was determined 
either from surgery records in cases where 
a special surgery was used (e.g. evisceration, 
enucleation) or based on the date of surgical 
excision of OSSN. The first cohort included 
patients who received simple surgical excision 
for OSSN during the time period 1 February 
1998 - 31 December 2001. The second cohort 
included patients who received excision with 
adjunctive beta radiation during the time 
period 1 January 2003 - 31 March 2008. 
Patients treated during the year 2002 were not 
included in either cohort, as it could not be 
determined whether these patients received 
adjunctive beta radiation or not. Patients 
were categorised as having CIN/dysplasia 
or invasive SCC of the conjunctiva based on 
the histological diagnosis from the pathology 
laboratory records. Duration of follow-up 
was based on visits to the ophthalmology 
clinic determined from the clinic’s records. 
HIV-related variables, including CD4 count, 
viral load and highly active antiviral therapy 
(HAART) status, were collected from 
Meditech, the computerised medical record 
system in place at PMH since 2004. Recurrence 
was defined as a repeat diagnosis of OSSN in 
the same eye after treatment of OSSN with 
surgical excision. We continued to monitor 
for recurrences in the pathology and surgery 
records through to 31 March 2009, all study 
patients being followed up for recurrences 
for a minimum of 12 months. Given that 
PMH is the ophthalmology referral centre for 
the southern half of Botswana, the estimated 
annual incidence of OSSN was calculated 
using half of the population of Botswana as 
the at-risk population. Sensitivity analyses 
were performed varying the proportion of 
the population treated at PMH from 25% 
to 75% to determine an upper and lower 
limit of the annual incidence estimate. The 
total population of Botswana according to 
the World Bank was used for these calcu-
lations.[19]
Statistical analyses were performed 
using STATA version 9.1 (USA). The study 
was approved by the Health Research and 
Development Committee of Botswana’s 
Ministry of Health as well as the institutional 
review boards at PMH and the University of 
Pennsylvania.
Results
During the 10-year period 1998 - 2007, 
468 patients were treated for OSSN by 
surgical excision at PMH. The estimated 
annual incidence of OSSN in Botswana 
increased over the study period from 2.6 
(range 1.0 - 5.3) cases per 100 000 persons 
in 1998 to a peak of 7.0 (range 4.7 - 14.0) per 
100 000 in 2004 (Fig. 1). The demographics 
and baseline clinical characteristics of the 
study population as well as the treatment 
modalities used are presented in Table 1. The 
mean age of the patients in the study was 38 
years (interquartile range (IQR) 30 - 44), and 
the majority (53.9%) were women.
The HIV status and median CD4 count of 
patients in the study are presented in Table 
1. Of the 180 (38.5%) HIV-infected patients 
who had CD4 counts available during the 
study period, 85 (47.2%) had CD4 counts 
<200 cells/µL and 152 (84.4%) had CD4 
counts <400 cells/µL. Forty-three of the 150 
patients (28.7%) with viral loads available 
had unsuppressed viral loads (>1 000 copies/
mL). Of the 85 patients with CD4 counts 
<200 cells/µL at any time during the study 
period (who would have been eligible for 
free HAART according to Botswana’s HIV 
guidelines at the time), 17 (20.0%) were on 
HAART prior to OSSN surgery, 13 (15.3%) 
were initiated on HAART within 1 year after 
surgery, 9 (10.6%) were initiated on HAART 
later in the study period, and 46 (54.1%) had 
no evidence of HAART initiation during the 
study period.
Five of the 7 (71.4%) confirmed HIV-
uninfected patients were under the age of 
45, and 6 (85.7%) were female. Two of the 
HIV-uninfected patients were diagnosed 
with CIN/dysplasia and 1 with SCC, and 4 
had no histological diagnosis available. All 
HIV-uninfected patients were treated with 
adjunctive beta radiation, and none experienced 
recurrences during the study period.
Of all 468 patients, 33 (7.1%) experienced 
known recurrences during the study period. 
Baseline clinical characteristics and initial 
treatments of patients who experienced 
recurrences are presented in Table 1 and 
data pertaining to timing and treatment 
of recurrences in Table 2. The mean age of 
patients who experienced recurrences was 36 
years (IQR 29 - 41), and 20 of the 33 patients 
(60.6%) who experienced recurrences were 
women. The median time to recurrence was 
6 months (IQR 2 - 17).
Only approximately half of the study 
patients (n=247, 52.7%) had documented 
ophthalmology clinic follow-up (mean 
duration of follow-up 13 months, IQR 1 - 21 
months) and only 95 patients (20.3%) had at 
least 6 months of follow-up. Among patients 
with at least 6 months of follow-up, 23 
(24.2%) had one or more recurrences. While 
10 of 97 patients (10.3%) treated with surgical 
excision alone and 18 of 332 (5.4%) treated 
with adjunctive beta radiation experienced 
recurrences, the actual recurrence rates 
in this population are therefore probably 
higher.
Discussion
This study of OSSN patients in Botswana 
contributes to the growing literature 
documenting the rising incidence of OSSN 
in SSA and its association with the HIV 
epidemic. The estimated annual incidence 
of OSSN in Botswana has risen from 0.13 
(range 0.09 - 0.27) cases per 100 000 persons 
in 1993[20] to a peak of 7.6 (range 5.0 - 
15.1) per 100 000 in 2004. This estimated 
incidence rate, which may be an under-
representation of the true incidence rate, is 
high even for SSA, as estimated incidences 
of OSSN from other countries in the region 
are 2.2/100 000 persons in Tanzania and 
2.1/100 000 in Uganda.[21,22] These differences 
in OSSN incidence may reflect differences in 
HIV prevalence; Botswana has an estimated 
adult HIV prevalence of 23.0%, whereas the 
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Fig. 1. Estimated annual incidence of OSSN per 100 000 persons in Botswana, 1998 - 2007.
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Table 1. Characteristics of patients treated for OSSN at PMH, February 1998 - March 2008
Characteristic Total (N=468) Recurrence (N=33) No recurrence (N=435)
Age group (years), n (%)
<20 14 (3.0) - 14 (3.2)
20 - 29 86 (18.4) 9 (27.3) 77 (17.7)
30 - 39 177 (37.8) 14 (42.4) 163 (37.5)
40 - 49 104 (22.2) 8 (24.3) 96 (22.0)
50 - 59 34 (7.3) 1 (3.0) 33 (7.6)
60-69 14 (3.0) 1 (3.0) 13 (3.0)
≥70 14 (3.0) - 14 (3.2)
Unknown 25 (5.3) - 25 (5.8)
Gender, n (%)
Male 185 (39.5) 13 (39.4) 172 (39.6)
Female 252 (53.9) 20 (60.6) 232 (53.3)
Unknown 31 (6.6) - 31 (7.1)
Eye affected
Right 186 (39.7) 16 (48.5) 170 (39.1)
Left 172 (36.8) 14 (42.4) 158 (36.3)
Both 4 (0.9) - 4 (0.9)
Unknown 106 (22.6) 3 (9.1) 103 (23.7)
HIV status, n (%)
Positive 227 (48.5) 22 (66.7) 205 (47.1)
Negative 7 (1.5) - 7 (1.6)
Unknown 234 (50.0) 11 (33.3) 223 (51.3)
CD4 count within 1 year of OSSN excision (cells/µL), median (IQR) 192 (122 - 288) 153 (76 - 221)
CD4 count <100 cells/µL, n (%) 42 (9.0) 6 (18.2) 36 (8.3)
CD4 count 101 - 200 cells/µL, n (%) 43 (9.2) 3 (9.1) 40 (9.2)
CD4 201-400 cells/µL, n (%) 67 (14.3) 5 (15.2) 62 (14.3)
CD4 > 400 cells/µL, n (%) 28 (6.0) 3 (9.1) 25 (5.7)
CD4 count unknown 288 (61.5) 16 (48.4) 272 (62.5)
HAART status, n (%) of confirmed HIV-infected patients
On HAART prior to initial OSSN surgery 39 (17.2) 3 (13.6) 36 (17.6)
Initiated on HAART after initial OSSN surgery 60 (26.4) 9 (40.9) 51 (24.9)
HAART status unknown 128 (56.4) 10 (45.5) 118 (57.5)
Initial histological diagnosis by pathologist, n (%)
SCC of conjunctiva 162 (34.6) 15 (45.4) 147 (33.8)
SCC of conjunctiva 102 (21.8) 15 (45.4) 87 (20.0)
Well-differentiated SCC of conjunctiva 38 (8.1) - 38 (8.7)
Moderately differentiated SCC of conjunctiva 4 (0.9) - 4 (0.9)
Superficial /surface SCC of conjunctiva 18 (3.8) - 18 (4.1)
Dysplasia/CIN 124 (26.5) 5 (15.2) 119 (27.3)
Carcinoma in situ 15 (3.2) 2 (6.1) 13 (3.0)
Severe dysplasia 34 (7.3) - 34 (7.8)
Moderate to severe dysplasia 14 (3.0) - 14 (3.2)
Moderate dysplasia 34 (7.3) 3 (9.1) 31 (7.1)
Mild to moderate dysplasia 16 (3.4) - 16 (3.7)
Mild dysplasia 6 (1.3) - 6 (1.4)
Ocular surface squamous neoplasia 5 (1.0) - 5 (1.1)
Conjunctival neoplasm not confirmed by biopsy 182 (38.9) 13 (39.4) 169 (38.9)
Continued ...
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and Uganda are 5.1% and 7.2%, respectively.[23,24] In accordance 
with the assertion that the rising incidence of OSSN in African 
countries is related to the HIV epidemic, studies from this region 
have reported high rates of HIV seropositivity among OSSN patients, 
ranging from 71% to 92%.[25-27] In the present study, 97.0% of patients 
with HIV tests available were HIV seropositive, though HIV status 
was unknown for 50.0% of patients in the study. Alternatively, the 
rising incidence of OSSN may be related in part to increased rates of 
detection of OSSN over time.
In keeping with previous studies from Africa,[2,21] the majority 
of OSSN patients in Botswana were in the 3rd, 4th or 5th decade 
of life. The mean age of OSSN patients in our Botswana patient 
population was 38 years, comparable to mean ages of 38.7 years and 
37.7 years in studies from Tanzania and Zimbabwe, respectively.[26,28] 
Interestingly, the present study and several previous studies from 
SSA found that HIV-uninfected patients who developed OSSN were 
not significantly older than those infected with HIV, suggesting that 
other causes independent of HIV infection, such as ultraviolet light or 
HPV infection, may play a role in the pathogenesis of OSSN among 
young Africans.[8,26,27] In the present study, OSSN displayed a slight 
female predominance, which has been reported in several other SSA 
studies.[21,25] The female predominance of OSSN in this region may 
reflect the higher HIV prevalence in women relative to men, which 
is certainly the case in Botswana (19.8% v. 13.9%).[18] In addition to 
affecting younger, mostly female, individuals in Africa, OSSN has 
been reported to be a more rapidly growing, aggressive tumour among 
SSA populations.[7] In support of this, 16 patients in the present study 
had invasive tumours that ultimately required evisceration (n=7) or 
enucleation (n=9), resulting in loss of the affected eye.
Emerging evidence suggests that OSSN may be an AIDS-
defining illness among patients in SSA. In the present study, the 
median CD4 count within 1 year of OSSN surgery was 192 cells/
µL (IQR  122 - 288), and more than half of the OSSN patients had 
CD4 counts  <200  cells/µL, consistent with a diagnosis of AIDS. A 
recent study from Tanzania reported that 85% of OSSN patients had 
CD4 counts <200 cells/µL, and the median CD4 count of patients 
at the time of presentation was 71 cells/µL.[25] Similarly, in Uganda 
the median CD4 count among HIV-infected OSSN patients was 
111 cells/µL (IQR 62 - 221), and 65% of HIV-infected OSSN patients 
died of AIDS-related complications at a median of 20 months after 
OSSN diagnosis.[8] Despite the fact that many patients have advanced 
HIV disease at OSSN diagnosis, evidence suggests that OSSN may 
be the first clinical manifestation of HIV infection in the majority of 
patients, and that patients may often be unaware of their HIV status 
at presentation with OSSN.[27,29] Together, these findings highlight the 
critical role of eye clinics in conducting HIV testing and referring 
patients for CD4 monitoring and HAART initiation, if appropriate. 
Given the high percentage of OSSN patients who are not only HIV-
infected but also have advanced HIV disease, this is likely to be a 
high-yield method of identifying patients who are eligible and would 
benefit from lifesaving HAART therapy but would otherwise not 
have been initiated on HAART because they have no other clinical 
manifestations of HIV infection.
Simple surgical excision is the mainstay of treatment for OSSN in 
Africa,[10] yet few studies have examined the efficacy of simple surgical 
excision for the prevention of recurrences in African populations. 
High rates of recurrence (16.6%, 31.2%) have been reported following 
surgical excision of OSSN in Tanzania and Kenya.[25,30] However, a 
countrywide study in Uganda reported a recurrence rate of 3.2% 
among OSSN patients treated with simple surgical excision with a 
median follow-up of 32 months,[8] suggesting that surgical excision 
alone may provide adequate prevention of recurrence if proper 
removal technique is employed. In the present study, we found an 
overall recurrence rate of 7.1% among OSSN patients in Botswana, 
but in patients with at least 6 months of follow-up, the rate increased 
to 24.2%. Our recurrence rate calculations are certainly limited given 
that follow-up data were not available for about half of the patients. 
As a result, we may have missed some patients who experienced 
recurrences because they failed to return to the eye clinic (e.g. 
because they died, sought treatment in the private sector, moved 
to another region or chose not to seek Western medical treatment 
despite clinically significant symptoms). In addition, the lack of data 
on other confounding variables, such as surgical margins, limits our 
ability to compare these two interventions statistically. However, the 
present data indicate that at least 1 in 10 patients who received simple 
Table 1. (continued) Characteristics of patients treated for OSSN at PMH, February 1998 - March 2008
Characteristic Total (N=468) Recurrence (N=33) No recurrence (N=435)
Initial OSSN surgery, n (%)
Simple excision 97 (20.7) 10 (30.3) 87 (20.0)
Excision + adjunctive beta radiation 332 (70.9) 18 (54.6) 314 (72.2)
Evisceration 4 (0.9) 1 (3.0) 3 (0.7)
Enucleation/eye removal 6 (1.3) 1 (3.0) 5 (1.1)
Unknown surgery (during year 2002) 29 (6.2) 3 (9.1) 26 (6.0)
 Table 2. Recurrences among OSSN patients (N=33) treated at 
PMH, 1998 - 2008 
Characteristic n (%)





Time to first OSSN recurrence (years)
<1 22 (66.7)
1 - 2 9 (27.3)
2 - 3 2 (6.0)
Treatment of OSSN recurrence
Simple excision 8 (18.2)
Excision + adjunctive beta radiation 30 (68.2)
Evisceration 3 (6.8)
Enucleation/eye removal 3 (6.8)
RESEARCH
383       May 2015, Vol. 105, No. 5
surgical excision experienced a recurrence, suggesting that adjunctive 
therapies may be needed to control recurrences adequately in this 
HIV-infected African population. Whether adjunctive beta radiation 
is an effective alternative is unclear from this dataset, but the results 
suggest that further investigation is needed.
Conclusion
This study of OSSN patients from Botswana affirms the rising 
incidence of OSSN in association with the HIV epidemic. Further 
research is warranted to determine whether surgical excision alone 
is sufficient to prevent recurrences in this population, or whether 
adjunctive therapy is required. The finding that young HIV-negative 
women are also affected by OSSN in SSA also warrants further 
investigation as to whether the epidemiology of OSSN is changing 
even outside of the HIV epidemic.
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